Estrogens Conj-Medroxyprogest Ac 0.625-5 mg (14) Oral Tablet / Estrogens Conj 0.625 mg (14) Oral Tablet 28 Day Pack
RxNorm 1000486

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 1000486 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: Estrogens Conj-Medroxyprogest Ac 0.625-5 mg (14) Oral Tablet / Estrogens Conj 0.625 mg (14) Oral Tablet 28 Day Pack.

The following semantic concepts and normalized strings are associated with this clinical entity:

PSN
Estrogens Conj-Medroxyprogest Ac 0.625-5 mg (14) Oral Tablet / Estrogens Conj 0.625 mg (14) Oral Tablet 28 Day Pack
AUI:6832237
GPCK
{14 (estrogens, conjugated (USP) 0.625 mg / medroxyprogesterone acetate 5 mg Oral Tablet) / 14 (estrogens, conjugated (USP) 0.625 mg Oral Tablet) } Pack
AUI:12372775
TMSY
{14 (estrogens, conjugated (USP) 0.625 mg / medroxyPROGESTERone acetate 5 mg Oral Tablet) / 14 (estrogens, conjugated (USP) 0.625 mg Oral Tablet) } Pack
AUI:12379304

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

PSNPrescribable

Prescribable Name (PSN):
Estrogens Conj-Medroxyprogest Ac 0.625-5 mg (14) Oral Tablet / Estrogens Conj 0.625 mg (14) Oral Tablet 28 Day Pack
(Atom ID: 6832237)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
Estrogens Conj-Medroxyprogest Ac 0.625-5 MG (14) Oral Tablet / Estrogens Conj 0.625 MG (14) Oral Tablet 28 Day Pack
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
1000486
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
6832237
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
PSN
Prescribable Name (Synonym of another TTY, given for clarity and for display purposes in electronic prescribing applications. Only one PSN per concept.)
Source Code
1000486
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

GPCKPrescribable

Generic Pack (GPCK):
{14 (estrogens, conjugated (USP) 0.625 mg / medroxyprogesterone acetate 5 mg Oral Tablet) / 14 (estrogens, conjugated (USP) 0.625 mg Oral Tablet) } Pack
(Atom ID: 12372775)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
{14 (estrogens, conjugated (USP) 0.625 MG / medroxyprogesterone acetate 5 MG Oral Tablet) / 14 (estrogens, conjugated (USP) 0.625 MG Oral Tablet) } Pack
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
1000486
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12372775
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
GPCK
Generic Pack ({# (Ingredient + Strength + Dose Form) / # (Ingredient + Strength + Dose Form)} Pack)
Source Code
1000486
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Technical Attributes & Logic

RXN HUMAN DRUG
US
Drug available for use in Humans

TMSYPrescribable

Tall Man Lettering Synonym (TMSY):
{14 (estrogens, conjugated (USP) 0.625 mg / medroxyPROGESTERone acetate 5 mg Oral Tablet) / 14 (estrogens, conjugated (USP) 0.625 mg Oral Tablet) } Pack
(Atom ID: 12379304)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
{14 (estrogens, conjugated (USP) 0.625 MG / medroxyPROGESTERone acetate 5 MG Oral Tablet) / 14 (estrogens, conjugated (USP) 0.625 MG Oral Tablet) } Pack
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
1000486
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12379304
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
TMSY
Tall Man Lettering Synonym (Tall Man Lettering synonym of another TTY, given to distinguish between commonly confused drugs.)
Source Code
1000486
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Patient Education

Estrogen


Estrogen is used to treat hot flushes ('hot flashes'; sudden strong feelings of heat and sweating) in women who are experiencing menopause ('change of life', the end of monthly menstrual periods). Some brands of estrogen are also used to treat vaginal dryness, itching, or burning, or to prevent osteoporosis (a condition in which the bones become thin and weak and break easily) in women who are experiencing or have experienced menopause. However, women who need a medication only to treat vaginal dryness or only to prevent osteoporosis should consider a different treatment. Some brands of estrogen are also to relieve symptoms of low estrogen in young women who do not produce enough estrogen naturally. Some brands of estrogen are also used to relieve the symptoms of certain types of breast and prostate (a male reproductive gland) cancer. Estrogen is in a class of medications called hormones. It works by replacing estrogen that is normally produced by the body.
[Learn More]


Estrogen and Progestin (Hormone Replacement Therapy)


Combinations of estrogen and progestin are used to treat certain symptoms of menopause. Estrogen and progestin are two female sex hormones. Hormone replacement therapy works by replacing estrogen hormone that is no longer being made by the body. Estrogen reduces feelings of warmth in the upper body and periods of sweating and heat (hot flashes), vaginal symptoms (itching, burning, and dryness) and difficulty with urination, but it does not relieve other symptoms of menopause such as nervousness or depression. Estrogen also prevents thinning of the bones (osteoporosis) in menopausal women. Progestin is added to estrogen in hormone replacement therapy to reduce the risk of uterine cancer in women who still have their uterus.
[Learn More]


* Please review the disclaimer below.